Cooper (COO) Q3 2026 Earnings Call Transcript

CooperCompanies reported Q3 revenue of $1.066 billion, up 1% organically, and non-GAAP EPS of $1.15, up 4% and above consensus for the 11th consecutive quarter; record free cash flow reached $273 million. CooperVision revenue was flat organically as proactive U.S. inventory destocking reduced Americas growth, while CooperSurgical grew 3% organically and fertility rose 5%. The board ended its strategic review and retained CooperSurgical, judging sale proposals inadequate, while repurchasing $339.1 million of stock and expanding authorization by $1 billion. Q4 guidance calls for $1.057-$1.080 billion of revenue, 0%-2% organic growth, and EPS of $1.05-$1.09, with FX, lower tariff refunds, commercial investments, and continued destocking pressuring margins.

Analysis

COO’s near-term setup is a valuation-versus-execution problem, not a demand collapse: the inventory reset should mechanically improve reported growth beginning in fiscal 2027, but management has also exposed a genuine commercial-capacity gap. The incremental sales-force build will likely delay operating leverage for two to three quarters before converting contract wins into revenue, making the December FY27 framework the key catalyst rather than the current quarter. A return to market-level contact-lens growth would support estimate revisions; failure to demonstrate that by the fiscal Q2-Q3 period would imply share loss rather than a one-time channel issue.

The decision to retain CooperSurgical removes a potential sum-of-the-parts catalyst and leaves COO more dependent on execution in CooperVision. However, fertility/genomics can become the offsetting growth engine if clinic investment and reimbursement expansion translate into sustained mid-single-digit-plus growth; the more immediate risk is that a new nonhormonal IUD entrant forces Paragard price concessions before fertility can carry the segment. The enlarged repurchase authorization provides a valuation floor, but incremental debt and a higher FY27 tax rate mean buybacks cannot mask weak organic growth indefinitely.

Consensus may be too focused on the reported Vision reset and insufficiently discounts the margin cost of restoring commercial coverage. Conversely, the market may underappreciate the earnings-quality improvement from eliminating inventory overhang, higher direct fulfillment penetration, and mix migration toward toric, multifocal, and myopia-management products. The bullish thesis requires FY27 organic growth at least in the contact-lens market range with stable gross margin despite FX, tariffs, and added selling expense; otherwise COO should de-rate as a mature medtech with sub-market growth.

Key Decisions for Investors

• Maintain a neutral/watch stance on COO into the December FY27 outlook rather than chase a post-results relief move. Upgrade only if management guides CooperVision to at least 4%-5% organic growth and preserves operating-margin expansion after commercial investment; this would validate a 6-12 month rerating case.
• For existing COO longs, use strength before the FY27 guide to trim exposure or buy 3-6 month downside protection. Key thesis failure points are another Vision growth reset, evidence that U.S. inventory normalization extends beyond Q4, or FY27 tax/interest pressure preventing EPS growth.
• Consider a 6-12 month pair trade: long COO / short XRAY only after FY27 Vision growth is validated. COO would offer cleaner recurring-consumables exposure and buyback support, while XRAY remains more exposed to discretionary dental procedure and capital-equipment sensitivity; avoid initiation until COO proves its sales-force spending converts to revenue.
• Monitor the competitive IUD launch and Paragard pricing in the December call. Any material price or volume erosion without acceleration in fertility/genomics growth is a signal to short COO versus the broader medical-device ETF IHI, as the lost separation catalyst and lower consolidated growth would pressure the multiple.